Bramah Singh

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Dose-dependent effects of oral dronedarone on the circadian variation of RR and QT intervals in healthy subjects: implications for antiarrhythmic actions
    Nitin Wadhani
    David Geffen School of Medicine at University of California, Los Angeles, USA
    J Cardiovasc Pharmacol Ther 11:184-90. 2006
  2. doi request reprint Augmenting maintenance of sinus rhythm in the control of atrial fibrillation by antiarrhythmic drug combinations
    Bramah N Singh
    Division of Cardiology, Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, CA, USA
    J Cardiovasc Pharmacol Ther 15:31S-5S. 2010
  3. ncbi request reprint Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs
    Bramah N Singh
    Division of Cardiology, Veterans Administration Greater Los Angeles Healthcare System and the David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, CA 90073, USA
    J Cardiovasc Pharmacol Ther 9:S85-97. 2004
  4. ncbi request reprint Amiodarone versus sotalol for atrial fibrillation
    Bramah N Singh
    Department of Veterans Affairs Medical Center, West Los Angeles, Calif 90073, USA
    N Engl J Med 352:1861-72. 2005
  5. ncbi request reprint Beta-Adrenergic blockers as antiarrhythmic and antifibrillatory compounds: an overview
    Bramah N Singh
    Department of Cardiology, VA Medical Center, West Los Angeles, David Geffen School of Medicine at UCLA, Los Angeles 90073, USA
    J Cardiovasc Pharmacol Ther 10:S3-S14. 2005
  6. ncbi request reprint Amiodarone: a multifaceted antiarrhythmic drug
    Bramah N Singh
    Cardiology Division, VA Greater Los Angeles Healthcare System, 11301 Wilshire Boulevard, West Los Angeles, CA 90073, USA
    Curr Cardiol Rep 8:349-55. 2006
  7. ncbi request reprint Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter
    Bramah N Singh
    Cardiology Division, Veterans Affairs Greater Los Angeles Healthcare System and the David Geffen School of Medicine at UCLA, Los Angeles, CA 90073, USA
    N Engl J Med 357:987-99. 2007
  8. doi request reprint Amiodarone as paradigm for developing new drugs for atrial fibrillation
    Bramah N Singh
    Department of Medicine, The David Geffen School of Medicine at UCLA, and the VA Greater Los Angeles Health System, West Los Angeles, California, USA
    J Cardiovasc Pharmacol 52:300-5. 2008
  9. doi request reprint Atrial fibrillation: from ion channels to bedside treatment options
    Bramah Singh
    David Geffen School of Medicine at UCLA, VA Greater Los Angeles Health Care System, 11301 Wilshire Boulevard, Los Angeles, CA 90073, USA
    J Electrocardiol 42:660-70. 2009
  10. doi request reprint A new agent for atrial fibrillation: electrophysiological properties of dronedarone
    Bramah N Singh
    Division of Cardiology, Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, CA, USA
    J Cardiovasc Pharmacol Ther 15:6S-14S. 2010

Detail Information

Publications37

  1. ncbi request reprint Dose-dependent effects of oral dronedarone on the circadian variation of RR and QT intervals in healthy subjects: implications for antiarrhythmic actions
    Nitin Wadhani
    David Geffen School of Medicine at University of California, Los Angeles, USA
    J Cardiovasc Pharmacol Ther 11:184-90. 2006
    ..Dronedarone resembled amiodarone in class III and sympatholytic effects, indicating its potential as a unique antiarrhythmic compound seemingly devoid of the side effects mediated by iodine in amiodarone...
  2. doi request reprint Augmenting maintenance of sinus rhythm in the control of atrial fibrillation by antiarrhythmic drug combinations
    Bramah N Singh
    Division of Cardiology, Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, CA, USA
    J Cardiovasc Pharmacol Ther 15:31S-5S. 2010
    ..This paper explores the possibility of augmenting the extent of controlling AF by combining multiple potent antiarrhythmic agents old and new...
  3. ncbi request reprint Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs
    Bramah N Singh
    Division of Cardiology, Veterans Administration Greater Los Angeles Healthcare System and the David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, CA 90073, USA
    J Cardiovasc Pharmacol Ther 9:S85-97. 2004
    ..The rationale for the therapeutic niche for amiodarone, and especially in the case of ranolazine, in the prevention of drug-induced torsades de pointes is discussed...
  4. ncbi request reprint Amiodarone versus sotalol for atrial fibrillation
    Bramah N Singh
    Department of Veterans Affairs Medical Center, West Los Angeles, Calif 90073, USA
    N Engl J Med 352:1861-72. 2005
    ..The optimal pharmacologic means to restore and maintain sinus rhythm in patients with atrial fibrillation remains controversial...
  5. ncbi request reprint Beta-Adrenergic blockers as antiarrhythmic and antifibrillatory compounds: an overview
    Bramah N Singh
    Department of Cardiology, VA Medical Center, West Los Angeles, David Geffen School of Medicine at UCLA, Los Angeles 90073, USA
    J Cardiovasc Pharmacol Ther 10:S3-S14. 2005
    ..This introduction provides a current perspective on these newer developments in the understanding of the antiarrhythmic and antifibrillatory actions of beta-blockers...
  6. ncbi request reprint Amiodarone: a multifaceted antiarrhythmic drug
    Bramah N Singh
    Cardiology Division, VA Greater Los Angeles Healthcare System, 11301 Wilshire Boulevard, West Los Angeles, CA 90073, USA
    Curr Cardiol Rep 8:349-55. 2006
    ..Deiodination and other structural changes in the amiodarone molecule have has led to a the loss of thyroid and pulmonary effects in the resulting derivative, dronedarone, which is in advanced clinical development...
  7. ncbi request reprint Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter
    Bramah N Singh
    Cardiology Division, Veterans Affairs Greater Los Angeles Healthcare System and the David Geffen School of Medicine at UCLA, Los Angeles, CA 90073, USA
    N Engl J Med 357:987-99. 2007
    ..Dronedarone is a new antiarrhythmic agent pharmacologically related to amiodarone but developed to reduce the risk of side effects...
  8. doi request reprint Amiodarone as paradigm for developing new drugs for atrial fibrillation
    Bramah N Singh
    Department of Medicine, The David Geffen School of Medicine at UCLA, and the VA Greater Los Angeles Health System, West Los Angeles, California, USA
    J Cardiovasc Pharmacol 52:300-5. 2008
    ..The resulting compound, dronedarone, is in advanced clinical development. It is likely the first amiodarone congener that will be used in the control of atrial fibrillation. Others are in earlier phases of development...
  9. doi request reprint Atrial fibrillation: from ion channels to bedside treatment options
    Bramah Singh
    David Geffen School of Medicine at UCLA, VA Greater Los Angeles Health Care System, 11301 Wilshire Boulevard, Los Angeles, CA 90073, USA
    J Electrocardiol 42:660-70. 2009
    ..Targeted antiarrhythmic therapies have the potential to provide safer and more effective management options for patients with atrial fibrillation...
  10. doi request reprint A new agent for atrial fibrillation: electrophysiological properties of dronedarone
    Bramah N Singh
    Division of Cardiology, Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, CA, USA
    J Cardiovasc Pharmacol Ther 15:6S-14S. 2010
    ..In this part of the supplement, the focus is the electrophysiological effects of dronedarone with the characterization in normal cardiac cells, in animal models of disease, as well as in human studies...
  11. ncbi request reprint Atrial fibrillation: epidemiologic considerations and rationale for conversion and maintenance of sinus rhythm
    Bramah N Singh
    Department of Cardiology VA Medical Center, West Los Angeles, and UCLA School of Medicine, Los Angeles, California 90073, USA
    J Cardiovasc Pharmacol Ther 8:S13-26. 2003
    ....
  12. ncbi request reprint The relevance of sympathetic activity in the pharmacological treatment of chronic stable angina
    B N Singh
    Division of Cardiology, VAMC of West Los Angeles, Department of Medicine, UCLA School of Medicine, Los Angeles, CA, USA
    Can J Cardiol 15:15A-21A. 1999
    ..These findings have important implications for the treatment of ischemia in patients with chronic stable angina...
  13. ncbi request reprint What niche will newer class III antiarrhythmic drugs occupy?
    B N Singh
    Division of Cardiology 111E, VA Medical Center of West Los Angeles, 11301 Wilshire Boulevard, Los Angeles, CA 90073, USA
    Curr Cardiol Rep 3:314-23. 2001
    ..The potential therapeutic niche of ibutilide, dofetilide, and azimilide in the control of cardiac arrhythmias forms the basis of this review...
  14. ncbi request reprint Significance and control of cardiac arrhythmias in patients with congestive cardiac failure
    Bramah N Singh
    VA Greater Los Angeles, Health Care System and the UCLA School of Medicine, Los Angeles, California, USA
    Heart Fail Rev 7:285-300. 2002
    ..Amiodarone and dofetilide are most widely used in this context...
  15. ncbi request reprint A practical guide for clinicians who treat patients with amiodarone: 2007
    Nora Goldschlager
    University of California, San Francisco, California, USA
    Heart Rhythm 4:1250-9. 2007
    ..The recommendations included herein are based on the best available data and the collective experience of the member of the writing committee...
  16. ncbi request reprint Metabolic modulators for chronic cardiac ischemia
    Pirouz Parang
    Department of Medicine, Robert Wood Johnson Medical School, New Brunswick, NJ, USA
    J Cardiovasc Pharmacol Ther 10:217-23. 2005
    ..This new paradigm promises to eliminate these side effects...
  17. ncbi request reprint Effects of N-acetylprocainamide and recainam in the pharmacologic conversion and suppression of experimental canine atrial flutter: significance of changes in refractoriness and conduction
    G K Feld
    Division of Cardiology, Wadsworth VA Medical Center, California
    J Cardiovasc Pharmacol 11:573-80. 1988
    ..01), functional refractory period (+20%, p less than 0.01), conduction time at atrial paced cycle length of 150 msec (+70%, p less than 0.01) and atrial flutter cycle length (+56%, p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)..
  18. ncbi request reprint Antithrombotic therapies for stroke prevention in atrial fibrillation
    C Economides Muñoz
    Department of Medicine, The Greater Los Angeles Veterans Affairs, Medical Center Healthcare Systems, West Los Angeles Medical Center, Los Angeles, CA, USA
    Minerva Cardioangiol 52:125-39. 2004
    ..In this context, the potential role of the direct thrombin inhibitors hold promise for the future and the evolving data on leading compounds of this class which may be competitive with warfarin are discussed...
  19. ncbi request reprint Exercise capacity in atrial fibrillation: a substudy of the Sotalol-Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T)
    J Edwin Atwood
    Cardiology Division, Walter Reed Army Medical Center, 6900 Georgia Ave NW, Washington, DC 20307, USA
    Am Heart J 153:566-72. 2007
    ..Therapy for chronic atrial fibrillation (AF) focuses on rate versus rhythm control, but little is known about the effects of common therapeutic interventions on exercise tolerance in AF...
  20. ncbi request reprint Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a Veterans Affairs Cooperative Studies Program Substudy
    Steven N Singh
    Department of Veterans Affairs Medical Center, Washington, DC 20422, USA
    J Am Coll Cardiol 48:721-30. 2006
    ..The purpose of this study was to determine quality of life (QOL) and exercise performance (EP) in patients with persistent atrial fibrillation (AF) converted to sinus rhythm (SR) compared with those remaining in or reverting to AF...
  21. ncbi request reprint Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation
    Elizabeth L Batcher
    West Los Angeles Veterans Affairs Medical Center, Los Angeles, Calif, USA
    Am J Med 120:880-5. 2007
    ..The purpose of this study was to determine the extent of amiodarone-induced thyroid dysfunction in a large male cohort...
  22. doi request reprint Rhythm control versus rate control for atrial fibrillation and heart failure
    Denis Roy
    Montreal Heart Institute and the Université de Montréal, Montreal, QC H1T 1C8, Canada
    N Engl J Med 358:2667-77. 2008
    ..However, the benefits and risks of this approach have not been adequately studied...
  23. ncbi request reprint Prolongation of repolarization as antifibrillatory action revisited: drug combination therapy in atrial fibrillation
    Nitin Wadhani
    J Cardiovasc Pharmacol Ther 10:149-52. 2005
  24. ncbi request reprint Mechanisms of antiarrhythmic drug actions and their clinical relevance for controlling disorders of cardiac rhythm
    Uma Srivatsa
    Department of Cardiology, VA Medical Center of West Los Angeles, 11301 Wilshire Boulevard, Los Angeles, CA 90073, USA
    Curr Cardiol Rep 4:401-10. 2002
    ..The continued development of newer pharmacologic agents is likely to lead to the resolution of the controversy regarding rhythm versus rate control in various clinical subsets of the arrhythmia by controlled clinical trials...
  25. ncbi request reprint Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol-Amiodarone Fibrillation Efficacy Trial [Safe-T])
    Steven N Singh
    Division of Cardiology, Veterans Affairs Medical Center, Washington, DC 20422, USA
    Am J Cardiol 92:468-72. 2003
    ..SAFE-T had randomized 665 patients when enrollment terminated on October 31, 2001. Follow-up of patients continued until October 31, 2002, for a maximum period of 54 months and a minimum period of 12 months for all patients...
  26. ncbi request reprint Ventricular rate control in atrial fibrillation: what is the optimal rate? The concept of controlling the heart rate burden
    Bramah N Singh
    J Cardiovasc Pharmacol Ther 8:1-3. 2003
  27. ncbi request reprint More on amiodarone--meeting the challenges of the combined epidemics of heart failure and atrial fibrillation?
    Bramah N Singh
    J Cardiovasc Pharmacol Ther 8:175-8. 2003
  28. ncbi request reprint Control of heart rate versus rhythm in rheumatic atrial fibrillation: a randomized study
    Amit Vora
    Department of Cardiology, King Edward VII Memorial Hospital, Mumbai, India
    J Cardiovasc Pharmacol Ther 9:65-73. 2004
    ..Which approach, ventricular rate control or maintenance of sinus rhythm, in this setting might be superior is not known. The role of amiodarone in this patient population for maintaining sinus rhythm has not been evaluated...
  29. ncbi request reprint Atrial fibrillation: the rate or rhythm controversy can it be resolved on the basis of clinical trial data?
    Bramah N Singh
    J Cardiovasc Pharmacol Ther 10:81-3. 2005
  30. ncbi request reprint Atrial fibrillation following investigation of rhythm management: AFFIRM trial outcomes. What might be their implications for arrhythmia control?
    Bramah N Singh
    J Cardiovasc Pharmacol Ther 7:131-3. 2002
  31. ncbi request reprint Antiarrhythmic drugs in cardiac arrest resuscitation: intravenous amiodarone or intravenous lidocaine?
    Bramah N Singh
    J Cardiovasc Pharmacol Ther 7:61-4. 2002
  32. ncbi request reprint Pursuit of sinus rhythm in patients with atrial fibrillation: is the effort worth it?
    Bramah N Singh
    J Cardiovasc Pharmacol Ther 9:219-21. 2004
  33. ncbi request reprint Classes of antianginal compounds: old and new--therapeutic implications
    Bramah N Singh
    J Cardiovasc Pharmacol Ther 8:85-8. 2003
  34. ncbi request reprint Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone
    Wei Sun
    Cardiovascular Research Laboratory, Department of Cardiology, VA Greater Los Angeles Health Care System of West Los Angeles, and UCLA School of Medicine, 90073, USA
    J Cardiovasc Pharmacol 39:677-84. 2002
    ..05; 182 +/- 11 V/s amiodarone, p < 0.05). Thus, chronic and acute electrophysiologic effects of dronedarone on rabbit atrial muscle are similar to those of amiodarone, suggesting a similar potential against atrial arrhythmias...
  35. ncbi request reprint Rate-dependence of antiarrhythmic drug action
    Bramah N Singh
    Department of Cardiology VA Medical Center, West Los Angeles, Los Angeles, CA 90073, USA
    J Cardiovasc Pharmacol Ther 7:203-6. 2002
  36. ncbi request reprint Atrial fibrillation: emerging possibilities for drug treatment: an overview of current opportunities and recent developments
    Julius Gy Papp
    Division of Cardiovascular Pharmacology, Hungarian Academy of Sciences and Szeged University, Szeged, Hungary
    J Cardiovasc Pharmacol Ther 8:S1-3. 2003
  37. ncbi request reprint Acute effects of zatebradine on cardiac conduction and repolarization
    Luyi Sen
    Division of Cardiology, Department of Medicine, VAMC West Los Angeles and UCLA School of Medicine, Los Angeles, CA 90024, USA
    J Cardiovasc Pharmacol Ther 7:29-38. 2002
    ..The inhibition of the AV nodal conduction and the lengthening of the refractory period and repolarization in the atria and the ventricles occur at higher dose...